Treatments for Alzheimer's disease (AD) directed against the prominent amyloid plaque
neuropathology are yet to be proved effective despite many phase 3 clinical trials.
There are several other neurochemical abnormalities that occur in the AD brain that
warrant renewed emphasis as potential therapeutic targets for this disease. Among
those are the elementomic signatures of iron, copper, zinc, and selenium. Here, we
review these essential elements of AD for their broad potential to contribute to Alzheimer's
pathophysiology, and we also highlight more recent attempts to translate these findings
into therapeutics. A reinspection of large bodies of discovery in the AD field, such
as this, may inspire new thinking about pathogenesis and therapeutic targets.